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ABSTRACT 
This Consensus Statement summarises recommendations for clinical diagnosis, investigation 
and management of patients with Silver–Russell syndrome (SRS), an imprinting disorder that 
causes prenatal and postnatal growth retardation. Considerable overlap exists between the 
care of individuals born small for gestational age and those with SRS. However, many 
specific management issues exist and evidence from controlled trials remains limited. SRS is 
primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical 
diagnosis and defines the subtype. A ‘normal’ result from a molecular test does not exclude 
the diagnosis of SRS. The management of children with SRS requires an experienced, 
multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, 
gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech 
delay and psychosocial challenges. An early emphasis on adequate nutritional status is 
important, with awareness that rapid postnatal weight gain might lead to subsequent 
increased risk of metabolic disorders. The benefits of treating patients with SRS with growth 
hormone include improved body composition, motor development and appetite, reduced risk 
of hypoglycaemia and increased height. Clinicians should be aware of possible premature 
adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with 
gonadotropin-releasing hormone analogues can delay progression of central puberty and 
preserve adult height potential. Long-term follow up is essential to determine the natural 
history and optimal management in adulthood.  
 
Silver–Russell syndrome (SRS, OMIM #180860, also known as Russell–Silver 
syndrome, RSS) is a rare, but well-recognised, condition associated with prenatal 
and postnatal growth retardation. The syndrome was first described by Silver et al. 1 
and Russell 2, who independently described a subset of children with low birth 
weight, postnatal short stature, characteristic facial features and body asymmetry. 
Almost all patients with SRS are born small for gestational age (SGA; Box 1). The 
aetiology of intrauterine growth retardation (IUGR) and SGA is extremely 
heterogeneous. Children with SRS can be distinguished from those with idiopathic 
IUGR or SGA and postnatal growth failure by the presence of other characteristic 
features, including relativemacrocephaly (defined as a head circumference at birth 
≥1.5 SDS above birth weight and/or length SDS), prominent forehead, asymmetry 
and feeding difficulties 3-6.  
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The incidence of SRS generally ranges from 1:30,000 to 1:100,000 7. In 2015, a study in 
Estonia 8 estimated an incidence of 1:70,000; however, only molecularly confirmed cases 
were included, which could have resulted in underdiagnosis. Overall, SRS is probably more 
common than some previous estimates have suggested, but the exact incidence remains 
unknown. 
 
An underlying molecular cause can currently be identified in around 60% of patients clinically 
diagnosed with SRS4. The most common underlying mechanisms are loss of methylation on 
chromosome 11p15 (11p15 LOM; seen in 30–60% of patients) and maternal uniparental 
disomy for chromosome 7 (upd(7)mat; seen in ~5–10% of patients) 4,9,10. However, the 
molecular aetiology remains unknown in a substantial proportion of patients.  
 
Although considerable overlap exists in the clinical care of individuals born SGA and those 
with SRS, many management issues are specific to SRS. These include notable feeding 
difficulties, severe postnatal growth failure with no catch-up, recurrent hypoglycaemia, 
premature adrenarche, fairly early and rapid central puberty, insulin resistance and body 
asymmetry. Identification of the molecular cause in many patients has also raised questions 
about the management in individual molecular subtypes of SRS. As evidence from controlled 
trials is limited, a consensus meeting was organised to develop guidelines for diagnosis and 
management of patients with SRS.  
 
This Consensus Statement was produced on behalf of the COST action BM 1208 (European 
Network for Human Congenital Imprinting Disorders, http://www.imprinting-disorders.eu), 
European Society of Pediatric Endocrinology (ESPE), Pediatric Endocrine Society (PES), 
Asian Pacific Pediatric Endocrine Society (APPES) and Sociedad Latino-Americana de 
Endocrinología Pediátrica (SLEP). 
 
[H1]  
Methods 
41 task force members from 16 countries, chosen for their publication record and expertise in 
SRS, collaborated to develop this consensus statement. They included paediatric 
endocrinologists, clinical geneticists, molecular geneticists, a gastroenterologist and five non-
voting representatives from a parent support group. Participants included representatives 
nominated by the council and clinical practice committees from four international paediatric 
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endocrine societies. All participants signed a conflict of interest declaration, and the 
consensus was supported by academic funding, without pharmaceutical support. A Delphi-
like consensus methodology was adopted11. A comprehensive literature search was 
conducted using PubMed and the search terms “Silver Russell syndrome” and “Russell Silver 
syndrome". Additional relevant articles on SGA, differential diagnoses and growth hormone 
(GH) were also identified by PubMed searches when supplementary information was 
necessary. A comprehensive review of >600 articles formed the basis of discussion by three 
working groups. These groups focused on clinical diagnosis (working group 1: E.W., J.S., 
K.H.C., M.E., R.D.; P.G.M., T.O., E.S., M.T., I.K.T.), molecular testing (working group 2: F.B., 
J.B., K.G., M.K., D.M., G.M., S.R., Z.T., T.E., D.J.G.M) or clinical management (working 
group 3: K.L.-S., S.M.O’C., J.H.D.,A;C.; D.B., E.G., A.G., A.H.-K., A.A.J., A.L., M.M., K.M., 
I.O.P., G.B., M.D.H., I.N.), with 10, 10 and 16 members, respectively. Preparations for the 
consensus took place over 10 months, including two preparatory meetings and regular 
teleconference discussions between the working group members. At the final consensus 
meeting, propositions and recommendations were considered by participants and discussed 
in plenary sessions, enabling reformulation of the recommendations if necessary. Where 
published data were unavailable or insufficient, experts’ clinical experiences and opinions 
were considered. Finally, all experts voted on the recommendations of each working group 
using the following system. 
A Evidence or general agreement allow full agreement with the recommendation 
B Evidence or general agreement are in favour of the recommendation 
C Evidence or general agreement are weak for the recommendation 
D There is not enough evidence or general agreement to agree with the 
recommendation 
 
Depending on the proportion of votes received, the strength of the recommendation was 
recorded as follows. 
+ 26–49% of the votes 
++ 50–69% of the votes 
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+++ ≥70% of the votes 
  
[H1] Clinical diagnosis 
SRS is currently a clinical diagnosis based on a combination of characteristic features. 
Molecular testing can confirm the diagnosis in around 60% of patients4. Molecular testing 
enables stratification of patients with SRS into subgroups, which can lead to more tailored 
management. However, molecular investigations are negative in a notable proportion of 
patients with characteristic clinical features of SRS. For these patients, an established clinical 
diagnosis enables access to appropriate support groups, treatment (including GH) and 
further research into the underlying incidence, natural history and aetiology of the SRS 
phenotype.  
 
However, the diagnosis of SRS can be difficult, as the condition varies widely in severity 
among affected individuals and many of its features are nonspecific 4-6. Until now, no 
consensus has been reached on the clinical definition of SRS. Historically, this lack of 
consensus has probably led to underdiagnosis and overdiagnosis, particularly by clinicians 
unfamiliar with SRS.  
Several clinical scoring systems for SRS have been proposed, which reflects the challenge in 
reaching a confident diagnosis 4,5,12-15. All the systems use similar criteria, but vary in the 
number and definition of diagnostic features required for diagnosis. The relative sensitivity 
and specificity of these scoring systems have been compared in patients with confirmed 
molecular diagnoses 14,15.  
 
[H2] Netchine–Harbison clinical scoring system  
The Netchine–Harbison clinical scoring system (NH-CSS; Table 1), which was proposed by 
Azzi and colleagues in 2015 15 is the only scoring system for the diagnosis of SRS that was 
developed using prospective data. Four of the six criteria are objective; protruding forehead 
and feeding difficulties remain subjective, but clear clinical definitions are given. Using the 
same cohort, the NH-CSS proved more sensitive (98%) than previous systems 4,14. The NH-
CSS also had the highest negative predictive value (89%), which gives a high degree of 
confidence that patients who have less than four of the six clinical criteria for diagnosis are 
truly unaffected by SRS. The system is easy to use in a busy clinical setting. The NH-CSS is 
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also flexible enough to use even if data are incomplete, which is important as the diagnosis is 
often made in infancy, before information about postnatal growth and BMI is available.  
Similarly to other clinical scoring systems, the NH-CSS has a low specificity (36%) 15, which 
could result in false positive results when the diagnosis is just based on clinical findings. 
Relative macrocephaly at birth (defined as a head circumference at birth ≥1.5 SDS above 
birth weight and/or length SDS). and protruding forehead are the two features in the NH-CSS 
that best distinguish SRS from non-SRS SGA (see supplemental table 1) 4,15-18. To maintain 
confidence in the clinical diagnosis if all molecular testing is normal, we recommend that only 
patients scoring at least four of six criteria, including both prominent forehead and relative 
macrocephaly, should be diagnosed as ‘clinical SRS’ (previously known as ‘idiopathic SRS’); 
see the flow diagram for investigation and diagnosis of SRS (FIG 1). 
[H2] Diagnosis in late childhood or adulthood 
All scoring systems for SRS have been developed and validated in paediatric cohorts. 
However, an increasing number of adults with a historical diagnosis of SRS are being seen 
by clinicians, particularly regarding their concerns about passing the condition on to their 
offspring (personal experience of working group 1 and 3). In these patients, a clinical 
diagnosis is frequently challenged by lack of early growth data. An attempt should be made 
to obtain photographs of the individual aged 1–3 years, especially the face in profile, as well 
as measurements at birth and in the first 2 years. No current evidence exists to support an 
alternative approach to diagnosis in adults.  
 
[H2] Additional clinical features 
In addition to the clinical features in the NH-CSS, several others are recognised in 
association with SRS, as shown in Table 2 and Supplementary Table 1 online. These 
characteristics are not specific to SRS, and might be present in children born SGA who do 
not have SRS, but at a lower frequency than in patients with SRS. However, a few features 
occur at a much higher rate in children with SRS than in those with SGA 4,15,16 . These 
features include low muscle mass, crowded or irregular teeth, micrognathia, down-turned 
mouth, clinodactyly and excessive sweating.  
 
Recommendations  
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1.1 SRS should remain primarily a clinical diagnosis. Molecular testing is useful for the 
confirmation and stratification of diagnosis in SRS. Lack of a positive molecular result 
does not exclude the diagnosis of SRS. (A+++) 
1.2 The flow chart (Figure 1) based on the NH-CSS, should be adopted for the 
investigation and diagnosis of SRS. (A++) 
1.3 In children <2 years, adolescents and adults, a reduced threshold for molecular testing 
might be required due to missing data. (A++) 
 
[H1] Molecular diagnosis 
[H2] Investigation and diagnosis 
A positive molecular test result provides useful confirmation of the clinical diagnosis (FIG 1). 
This result also enables stratification into a specific molecular subgroup that, in turn, can help 
guide appropriate management. However, many patients are referred for molecular testing 
with few, or atypical, features of SRS, which leads to low diagnostic yields and incurs 
unnecessary expense 19. We therefore recommend the use of the flow chart in Figure 1 to aid 
in the investigation and diagnosis of SRS.  
Some patients, particularly those with upd(7)mat, have fewer typical clinical features of SRS 
than patients with 11p15 LOM 4,5,13,16,20,21. In the cohort reported by Azzi and co-workers 15, 
one of the nine patients scoring three of six criteria (and therefore predicted ‘unlikely to have 
SRS’) had upd(7)mat. The threshold recommended in FIG 1 for molecular testing (≥3 of six 
criteria) is, therefore, lower than that needed for a clinical diagnosis of SRS (≥4 of six 
criteria).  
Conversely, in the same cohort, no positive molecular diagnoses were made in patients 
scoring less than three of six criteria 15. Other studies have also excluded 11p15 LOM and 
upd(7)mat in patients born SGA with postnatal growth retardation but without additional 
features of SRS 4,10,22. We, therefore, do not recommend testing for SRS in patients scoring 
less than three of six criteria. Of note, a small number of patients with body asymmetry have 
been reported to have 11p15 LOM without associated growth retardation, probably due to 
tissue mosaicism 20,21,23. These patients would score less than three of six criteria, insufficient 
to justify a clinical diagnosis of SRS in these patients. 
 
[H2] Chromosome 11p15  
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Both SRS and the overgrowth condition Beckwith–Wiedemann syndrome are associated with 
molecular abnormalities of chromosome 11p15.5, which contains two imprinted domains 
(Figure 2). Imprinting of the telomeric domain, which is strongly implicated in SRS 24,25, is 
controlled by the paternally-methylated imprinting control region H19/IGF2 IG-DMR 
(H19/IGF2 intergenic differentially-methylated region), previously known as IC1, ICR1 and 
H19 DMR). The centromeric domain contains the maternally-expressed growth repressor 
CDKN1C; the imprinting of this gene is controlled by the maternally-methylated imprinting 
control region KCNQ1OT1 TSS-DMR (previously known as IC2, ICR2, LIT1 or KvDMR1). 
FIG 3 summarises the more common molecular changes of chromosome 11p15 associated 
with SRS. Hypomethylation of the H19/IGF2 IG-DMR results in reduced paternal IGF2 
expression and increased maternal H19 expression, which leads to growth restriction 9. 
Numerous copy number variants (CNVs) involving the 11p15.5 region have been reported; 
the phenotype dependent on CNV size, location and parental origin 24,26 (supplementary table 
2 online). 
Molecular testing must robustly and accurately measure DNA methylation of CpG 
dinucleotides at H19/IGF2 IG-DMR 27. Assays involve either bisulphite analysis 28-30 or 
enzymatic methods, such as methylation-specific multiplex ligation-mediated PCR 
amplification (MS-MLPA) or Southern blotting 9,31. The most common test in diagnostic use is 
MS-MLPA, which is economical on DNA, cost-effective and enables parallel analysis of copy 
number and DNA methylation 31,32. Hypomethylation of H19/IGF2 IG-DMR is frequently 
incomplete and low levels of hypomethylation might elude detection. Methylation patterns 
might vary between different tissues and cells (leucocytes, samples from a buccal swab and 
skin fibroblasts) 21,33,34 and could explain cases of a negative molecular diagnosis using a 
blood sample. 
Although copy number change can be detected by MS-MLPA, additional array analysis might 
be effective in characterising the size and gene content of any CNV identified.  
 
[H2] Chromosome 7 
Of individuals with SRS, ≤10% have upd(7)mat 35,36. The SRS phenotype of upd(7)mat is 
thought to result from altered expression of an imprinted growth-regulatory gene (or genes) 
37. In addition, the duplication of pre-existing pathogenic variations by isodisomy can lead to 
the clinical expression of recessive disorders (such as cystic fibrosis) in upd(7)mat 38-40  
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Candidate SRS regions have been suggested through identification of patients with 
segmental upd(7)mat or CNVs (supplementary table 3) and the primary candidate SRS 
genes on chromosome 7 are currently GRB10 (7p12.1) and MEST (7q32)41-48. 
.  
Microsatellite analysis was the first diagnostic test for upd(7)mat 35,36; however, this analysis 
cannot detect imprinting defects (epimutations) and requires DNA from at least one parent. 
DNA methylation analysis, including at least the imprinting control regions GRB10 alt-TSS 
DMR and MEST alt-TSS DMR, can identify upd(7)mat, epimutations, CNVs and segmental or 
whole-chromosome variations. DNA methylation analysis, for example by MS-MLPA, is 
economical on DNA, cost-effective and compatible with parallel analysis of 11p15 30,49,50.  
 
[H2] Additional testing  
If testing of both 11p15 and chromosome 7 is negative, additional molecular testing can be 
considered. 
[H3] CNVs. Over 30 different pathogenic CNVs have been described in patients with 
suspected SRS 15,51-53; a Leiden Open Variation Database (LOVD)  entry for structural 
variations is currently in submission). Patients with these CNVs usually have more severe 
developmental delay and/or intellectual disability than is typically seen in SRS 52,53. Some 
patients fulfil the NH-CSS for diagnosis; others either do not meet NH-CSS criteria, or 
insufficient data are given to use the criteria for their assessment. Although features of SRS 
can be present in individuals with a pathogenic CNV, clinical diagnosis of SRS is not helpful 
in these cases and management needs to be tailored specifically to the phenotypic 
consequences of the individual CNV.  
While either array comparative genomic hybridization or single nucleotide polymorphism 
array can be used to detect CNVs, single nucleotide polymorphism array can also detect 
regions of segmental isodisomy 54. 
[H3] Chromosome 14q32 abnormalities. Molecular abnormalities at the paternally-methylated 
imprinted locus on chromosome 14q32 include upd(14)mat, paternal microdeletions and 
hypomethylation of the DLK1/GTL2 IG-DMR (also referred to as MEG3-DMR, 14q32 DMR or 
IG-DMR). These result in Temple syndrome, which has clinical overlap with SRS 55,56, 
including being born SGA, postnatal growth retardation, hypotonia, delay in the development 
of motor skills  and early puberty 55.  
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In cohorts of patients with SRS, a small number of patients have been found to have Temple 
syndrome: 1 of 127 patients 57, 2 of 85 patients 56 and 1 of 26 patients 15. However, the true 
incidence of 14q32 abnormalities in patients meeting the NH-CSS criteria for diagnosis 
remains unknown. 
[H3] upd(20)mat and upd(16)mat. Patients with both upd(20)mat and upd(16)mat have 
occasionally been detected among cohorts of patients investigated for prenatal and postnatal 
growth failure or SRS 15,57,58. However, in a study published in 2015, none of eight patients 
with upd(20)mat had relative macrocephaly or asymmetry 59 , two important criteria of the NH-
CSS, so that these patients might have eluded formal clinical diagnosis of SRS. 
[H3] CDKN1C and IGF2 mutations. CDKN1C and IGF2 are the coding genes on 
chromosome 11p15 that are responsible for the growth anomalies in SRS and Beckwith–
Wiedemann syndrome. Maternally-transmitted SRS was described in a four-generation family 
with a CDKN1C gain-of-function mutation 60, and paternally-transmitted SRS in a family with 
an IGF2 loss-of-function mutation 61. However, no additional mutations have been reported to 
date in sporadic or familial cases of SRS 60,62,63. Sequence analysis of either gene may be 
considered, particularly in familial cases of SRS where the inheritance pattern is consistent 
but coding variants in these genes are rare 60,62,63. 
[H3] Multi-locus imprinting disturbance. A significant proportion (15–38%) of individuals with 
11p15 LOM have multi-locus imprinting disturbance (MLID) 33,57,64-66. High-density methylation 
arrays have revealed methylation changes involving both (maternally and paternally) 
imprinted and non-imprinted loci 67,68. However, despite welcome advances in genome-wide 
methylation screening 67,69,70, standardisation is required to ensure accurate description of 
MLID and comparison between cohorts. 
The effect of MLID on clinical phenotype remains unclear. No difference in growth 
parameters was found at birth or at 2 years of age between patients with 11p15 LOM with 
and without MLID 64. Although developmental delay and congenital anomalies were reported 
in patients with MLID, this finding might have been affected by ascertainment bias 57.  
In principle, MLID might be caused by trans-acting genetic mutations that affect the 
acquisition or maintenance of imprints, but in practice, very few have been identified 71,72. 
Although yet to be identified, such mutations may also be present in individuals with MLID 
presenting as SRS. 
Overall, the effect of MLID on clinical phenotype and its relevance for genetic counselling 
remain uncertain. Further information is needed before recommending testing for MLID 
outside the research setting.  
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Recommendations 
2.1  Molecular genetic testing should be performed by a health professional experienced in 
the field of imprinting disorders. Consistent and logical nomenclature should be 
adopted in publications and in test reporting. (A+++) 
2.2 First-line molecular testing should include DNA methylation analysis of the H19/IGF2 
IG-DMR and KCNQ1OT1 TSS DMR. (A+++) 
2.3 First-line molecular testing should include analysis of DNA methylation at the GRB10 
alt-TSS DMR and the MEST alt-TSS DMR. (A+++) 
2.4 In case of a positive test result at either 11p15 or chromosome 7, discrimination 
between epimutation, CNV and upd should be considered to estimate recurrence risk. 
(A+++) 
2.5 After exclusion of changes in 11p15 and chromosome 7, a clinical decision should be 
sought about the direction of further testing. Depending on the clinical features and 
family history of the patient, further testing might include CNV analysis and DNA 
methylation analysis at chromosome 14q32. Testing might also be considered for very 
rare molecular anomalies, including upd(20)mat, upd(16)mat and mutations in 
CDKN1C and IGF2, as well as analysis of further tissues to detect somatic mosaicism. 
(A++)  
2.6 When an underlying pathogenic CNV is identified, the diagnosis should focus on this 
feature, even if features of SRS are present. (A+) 
 
[H2] (Epi)genotype–phenotype correlation 
The frequency of individual features in specific SRS subgroups (11p15 LOM, upd(7)mat and 
clinical SRS) and patients with SGA but not SRS, where data are available, are shown in 
Supplementary Table 1 online. Genotype–phenotype studies of patients with SRS indicate 
considerable overlap in clinical phenotype between (epi)genotypes, and these are generally 
clinically indistinguishable. However, some features are more common in particular molecular 
subgroups 4,13,15-17,20,73.  
Patients with 11p15 LOM tend to have a lower birth length and weight, more frequent body 
asymmetry and more frequent congenital anomalies than patients with upd(7)mat. 
Neurocognitive problems are more frequent in patients with upd(7)mat than those with 11p15 
LOM or clinical SRS 15,16,20 (see later section on neurocognitive problems).  
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Patients with 11p15 duplication encompassing H19/IGF2 IG-DMR and KCNQ1OT1 TSS-
DMR have an SRS phenotype, but usually without asymmetry and with an increased 
likelihood of developmental delay (reviewed in 53). Of 15 patients reported to have 11p15 
duplication encompassing H19/IGF2 IG-DMR and KCNQ1OT1 TSS-DMR, four were noted to 
have hearing loss 74.  
 
[H2] Differential diagnosis  
The differential diagnosis of children with short stature of prenatal onset includes many 
syndromic diagnoses and chromosomal rearrangements (75 and see Tables 3 and 4). 
Particular features should prompt consideration of diagnoses other than SRS. These include 
relative microcephaly (head circumference SD score (SDS) below height and weight SDS), 
notable global developmental delay or intellectual disability (without a related explanation 
such as documented hypoglycaemia), absence of severe feeding difficulties, and/or the 
presence of additional congenital anomalies, facial dysmorphism or other features atypical for 
SRS. Disproportionate short stature is suggestive of skeletal dysplasia. Photosensitive skin 
rash or recurrent bronchopulmonary infections should prompt investigation for chromosome 
breakage disorders. As SRS is generally sporadic, a family history of growth failure and/or 
consanguinity might suggest an alternative underlying diagnosis 76. The clinical features of 
the most important and/or likely differential diagnoses are summarised in Tables 3 and 4. 
A correct diagnosis can have extremely important implications for management. Response to 
GH treatment, if given, varies depending on the underlying syndromic diagnosis. For 
instance, GH treatment is contraindicated in patients with chromosome breakage disorders, 
such as Bloom syndrome, due to the associated risk of malignancy 77. GH treatment in 
patients with SHORT syndrome has been reported to precipitate insulin resistance and 
subsequent type 2 diabetes mellitus 78. Therefore, an incorrect diagnosis of SRS leading to 
the recommendation of GH treatment could have adverse consequences in these patients. 
Three patients have been reported with clinical features of SRS but a molecular diagnosis of 
osteogenesis imperfecta, with a COL1A1 mutation 79,80 one with no history of fractures. Both 
SRS and OI can cause prenatal onset of growth failure, relative macrocephaly, large 
fontanelle, blue sclerae and body asymmetry. Both diagnoses should therefore be 
considered in patients with features overlapping both conditions. 
 
Recommendations 
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3.1 An alternative syndromic diagnosis, and specific investigation for this diagnosis, should 
be particularly considered in patients with any of the following: additional features 
atypical for SRS, family history of growth failure and/or consanguinity. (A+++) 
3.2 Patients with features of SRS overlapping with osteogenesis imperfecta should have a 
skeletal survey to look for additional evidence for osteogenesis imperfecta, with 
consideration of COL1A1/2 gene testing. (A++) 
 
[H1] Management 
SRS leads to a wide spectrum of abnormal physical characteristics and functional 
abnormalities. Multi-disciplinary follow-up and early, specific, intervention are necessary for 
optimum management of this group of patients.  
 
Recommendation 
4.1 Patients with SRS should receive multi-disciplinary care in a centre of expertise in SRS 
in co-ordination with their local centre. The multi-disciplinary team should be composed 
of paediatric subspecialists such as an endocrinologist (co-ordinator), 
gastroenterologist, dietician, clinical geneticist, craniofacial team, orthopaedic surgeon, 
neurologist, speech and language therapist and psychologist. (A+++) 
 
[H2] Early feeding and nutritional support 
The typical neonate with SRS has length SDS below weight SDS; but after birth, due to poor 
appetite, feeding difficulties and gastrointestinal problems, weight SDS drops below the 
length SDS 4,17,73,81. Over time, progressive failure to thrive can result in a calorie-related 
length deficit 4,15,82. 
Feeding difficulties and failure to thrive are considerably more frequent in patients with SRS 
than in children with SGA but not SRS 4,17. Failure to thrive in children with SRS is probably 
due to a combination of factors, including feeding difficulties (poor appetite, oromotor issues 
and the resulting low caloric intake) as well as functional and structural gastrointestinal 
problems. Digestive problems or malnutrition occur in over 70% of patients with SRS 82, 
including severe gastrooesophageal reflux in 55%, which often results in persistent vomiting 
after the age of 1 year. Constipation is also common, particularly after age 2 82. 
Cyproheptadine used as an appetite stimulant improves weight gain in other paediatric 
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conditions 83,84; however, specific studies of its use in SRS are needed before it can be 
recommended in these patients.  
The main therapeutic goals for the first 2 years of life in patients with SRS are nutritional 
support, prevention of hypoglycaemia and recovery of any calorie-related length or height 
deficit, which should be addressed before initiation of GH therapy (see following sections on 
prevention of hypoglycaemia and GH therapy). However, careful monitoring is needed, 
especially during non-volitional feeding, because rapid catch-up weight gain in children born 
SGA has been associated with an increased risk of metabolic and cardiovascular disease in 
later life 85.  
Children with SRS have an abnormal body composition with low muscle mass, and are 
typically light for their length or height 3,15,86,87. From our experience, the target for healthy 
nutritional status is narrow, and is dependent on individual innate muscle mass and even 
slight overnourishment (for example, weight >90% of ideal weight for length or height) can 
rapidly increase relative fat mass. Suggested targets for children aged 2–4 years preparing 
for GH therapy are: weight 75–85% of the 50th centile weight for length or height and/or BMI 
12–14 kg/m2, using height measurements on the longer side if notable leg length discrepancy 
is found (see following section on GH therapy). A weight below 70% of the ideal weight for 
length or height compromises growth velocity, despite GH treatment. For children older than 
4 years, the optimal target BMI will depend on their muscle mass. Two groups of patients are 
exceptions to this observation. Firstly, in patients with 11p15 LOM who have a very low 
muscle mass and considerable asymmetry, a lower BMI may be adequate (11–12 kg/m2). 
Secondly, in patients with upd(7)mat with near normal muscle mass, a higher BMI may be 
adequate (14–15 kg/m2).  
 
Recommendations 
5.1  For nutritional goals in the first years of life, we recommend nutritional repletion* with 
awareness of possible hazards of rapid postnatal catch-up leading to subsequent 
increased metabolic risk. (A +++) 
5.2 Ask for and/or screen early for gut dysmotility (gastrooesophageal reflux, delayed 
gastric emptying and constipation) in all children. (A+++) 
5.3 Diagnose and treat any oromotor and/or sensory issues that affect oral intake of food. 
(A+++) 
5.4 In patients with severe feeding failure who are unresponsive to standard care, 
anatomical or functional disorders of the gastrointestinal tract, such as malrotation, 
should be excluded. (A+++) 
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5.5 Avoid enteral feeding by nasogastric or gastrostomy tube in a child capable of eating 
where there is adequate nutritional repletion. (A+++) 
5.6 In cases of extreme feeding difficulties or gastrooesophageal reflux, consider enteral 
feeding by gastrostomy tube (with or without fundoplication) or low-profile transgastric 
jejunostomy as a last resort to protect against hypoglycaemia and/or malnutrition. 
(A+++) 
5.7  In the case of enteral feeding, prevent excessive weight gain in both volitionally and 
nonvolitionally fed children. (A++) 
*Low muscle mass makes typical BMI targets excessive in this population. Targets currently used in 
some centres include: Waterlow score 75–85% 88; weight-for-length SDS -2 to -1 in first year of life; 
BMI target SDS between -2 to -1 after first year of life. 
 
[H2] Prevention of hypoglycaemia 
Young children with SRS, particularly under age 5, have a disproportionately large brain-for-
body size, low muscle and liver mass, and feeding difficulties, all of which increase their risk 
of fasting hypoglycaemia and its potential neurocognitive consequences. The incidence of 
hypoglycaemia in these children is approximately 27% 20, with a high frequency of 
spontaneous, asymptomatic nocturnal hypoglycaemia 89.  
Monitoring of urinary ketones levels is usually effective in pre-empting hypoglycaemia related 
to fasting, activity or illness. This measurement can be used to determine the ‘safe fasting 
time’ for a child, which will change with age. Night time hypoglycaemia can be prevented by 
adding either high molecular weight glucose polymer (for infants under 10 months) or 
uncooked corn starch (for older infants and children particularly at risk) to the last evening 
feed. Dental hygiene is important as complex carbohydrates can promote cavities 90. Severe, 
non-fasting and non-ketotic hypoglycaemia should always be identified and investigated 
further. 
For episodes of preoperative fasting or febrile illness, intravenous glucose (10% dextrose) 
might be required. Children with SRS might need longer periods of gut rest than SGA 
children without SRS before oral or enteral feeding because of their gut dysmotility and 
intrinsic feeding defects. Before discharge, it is advisable to achieve an absence of ketonuria 
following at least 12 h of feeding, without intravenous support. When hypoglycaemia remains 
a problem, early GH therapy should be considered 91,92 (see following section on GH 
therapy).  
 
Recommendations 
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6.1 Monitoring for ketonuria at home is useful to determine which children need intervention 
for impending hypoglycaemia. (A++)* 
6.2 Develop a plan with the child’s local paediatrician and emergency room for rapid 
admission and intravenous dextrose treatment when the child is ill. (A++) 
6.3 Admit children with SRS to hospital early in the course of an illness associated with 
ketonuria or hypoglycaemia and do not discharge them until they are metabolically 
stable and can be adequately fed. (A++) 
6.4 Glucagon is not recommended to correct hypoglycaemia, because of poor glycogen 
stores and limited ability for gluconeogenesis. (A+++) 
6.5 Provide parents with an emergency guidance plan for illnesses. (A+++) 
6.6 Teach parents how to recognize signs of hypoglycaemia, measure ketones, determine 
the ‘safe fasting time’ for their child, prevent hypoglycaemia using complex 
carbohydrates and avoid fasting outside a controlled environment. (A+++) 
6.7 In severe cases of fasting hypoglycaemia, where other causes have been excluded and 
if other alternatives are ineffective, consider: 
• Early start of GH therapy to support glucose sources (increase in muscle 
mass and gluconeogenesis) (A++) 
• Placement of a gastrostomy tube or jejunjunostomy tube. (A++) 
 
*Children with a history of hypoglycaemia who do not have an appropriate ketone response will require 
formal fasting studies.  
 
[H2] Surgery and anaesthesia 
Any surgery should be carefully planned due to the increased risk of fasting hypoglycaemia in 
patients with SRS 93. As a result of their diminished weight-for-height ratio, low BMI and large 
head, young patients with SRS are at risk of hypothermia in a cool operating room 94. Many 
children with SRS also have abnormal tooth distribution and a small mandible, which affects 
airway visualization and intubation 95. Finally, young children with SRS who are malnourished 
might not heal well following surgery 96.   
 
Recommendations 
7.1 Review issues related to SRS with the anaesthetist and surgeon in advance. (A+++) 
7.2 Consider admission the night before surgery for early administration of intravenous 
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dextrose before surgery to avoid ketonuria and hypoglycaemia. (A++) 
7.3 Schedule first on the surgical list where possible. (A++) 
7.4 Monitor blood glucose and administer intravenous dextrose during and after surgery. 
Do not discharge until ketonuria is absent and the child can sustain themselves on oral 
or enteral feeding. (A++) 
7.5 Follow the intraoperative temperature maintenance protocol appropriate for the 
patient’s size, not age. (A+++) 
7.6 Delay elective surgery until the child is adequately nourished. (B+)  
7.7 Be aware of the high risk of malnutrition after surgery and follow appropriate guidelines. 
(A+)  
 
[H2] Growth hormone treatment 
Data on adult height in untreated patients with SRS are limited; however, SRS is associated 
with a significant reduction in adult height (around -3 SDS; supplementary table 4 online and 
3). SRS is an indication for growth-promoting GH treatment under the SGA registered licence. 
It is worth noting that SRS was the only syndrome to be included in the clinical trials of GH in 
short children born SGA that led to the US FDA and the European Medicines Agency (EMA) 
SGA indications for GH therapy in 2001 and 2003, respectively 97-101. Therefore, the results of 
these clinical trials validate the use of GH for SRS patients. 
Overall, clinical trials of GH treatment in patients with SGA (in which patients with SRS were 
included) demonstrated a satisfactory growth response and an increase in predicted adult 
height of 7–11 cm at pharmacological doses of GH 97-100,102. However, the response in 
patients with SRS was not investigated until a Dutch longitudinal study analysed the 
response to GH in 62 children with a clinical diagnosis of SRS using the NH-CSS compared 
with 227 short, non-syndromic children born SGA. Overall, the study showed a similar 
response to GH in patients with SRS compared with non-SRS children born SGA (mean total 
height gains of 1.30 SDS and 1.26 SDS, respectively); however, the final adult height 
attained in patients with SRS was lower (mean adult height -2.17 SDS versus -1.65 SDS for 
non-SRS children born SGA) 87. Although the mean height at the start of GH treatment in 
patients with SRS was statistically significantly lower than in those without SRS, it was shown 
that patients with all SRS subtypes benefited from GH treatment, with a trend towards 
increased height gain in patients with upd(7)mat or clinical SRS. In addition, some interim 
102100 and long-term 103,104 studies have focused on the response to GH specifically in patients 
with SRS, albeit without a control group of non-SRS short children born SGA. Strong 
predictors of the short-term and long-term responses to GH were age and height SDS at the 
start of GH treatment (both inversely related) 103-105. However,  the study of Rakover et al105 of 
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33 patients with SRS lacked data on adult height. Mean total height gain ranged from +1.2 to 
+1.4 SDS for GH doses of 35–70 µg/kg per day which is similar to that achieved in patients 
with non-syndromic SGA 97,103,104. In 2007, an SGA consensus statement advocated early 
treatment with GH for children born SGA, including those with SRS, who had severe growth 
retardation (height SDS ≤2.5; age 2–4 years; dose 35–70 µg/kg per day 106. 
Additional potential benefits of GH treatment are increases in appetite, lean body mass and 
muscle power, which can result in improved mobility 86,107. In patients with Prader–Willi 
syndrome, another imprinting disorder, GH treatment was started in infancy and resulted in 
increased lean body mass and motor development, as well as decreased fat mass 108,109; 
consequently GH treatment is now recommended from infancy in this condition. SRS children 
under age 2 typically present with low muscle mass and hypotonia, like Prader-Willi 
syndrome patients 15 and could also benefit from early GH treatment. Further studies are 
necessary to investigate this in patients with SRS. 
Classic GH deficiency is neither a common nor a relevant cause of short stature in SRS, nor 
is it predictive of the response to GH treatment in children born SGA 103,105,110. Furthermore, 
given the risk of hypoglycaemia associated with fasting required for GH testing, testing 
children with SRS might carry added risks.  
For most children with SRS, an increase in height velocity of ≥3 cm per year is the lower limit 
of an effective response range 106. The growth response depends on the patient's age, GH 
dose, height deficit, rate of weight gain and confounding problems such as intercurrent illness 
and scoliosis.  
Levels of insulin-like growth factor 1 (IGF-1) in response to GH treatment in patients with 
SRS are difficult to interpret. Children with 11p15 LOM have significantly higher IGF-1 levels 
than children with upd(7)mat and other children born SGA, which suggest an element of IGF-
1 resistance in patients with 11p15 LOM 73,111. Basal serum levels of IGF-1 in the upper 
quartile of the normal age-related range or higher can be expected in children with SRS, 
especially those with 11p15 LOM 73. In children with 11p15 LOM, serum levels of insulin-like 
growth factor-binding protein 3 (IGFBP-3) are also elevated 111. IGF-1 levels might rise 
significantly above the reference range in children with SRS on standard doses of GH 87,111. 
Further studies are needed to understand how best to use IGF-1 and IGFBP-3 serum levels 
to monitor GH dose in children with SRS and IGF-1 resistance. 
Comprehensive reviews on the use of GH in children born SGA have concluded that GH 
treatment seems to be safe and effective 112. Adverse effects due to GH treatment are no 
more frequent in children with SRS than in those with non-syndromic SGA 87,113 and no 
specific precautions are advised.  
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Recommendations 
8.1 Defer GH treatment until caloric deficits are addressed. (A++) 
8.2 Avoid GH stimulation testing. (A++) 
8.3 Goals of GH treatment are to improve body composition (especially lean body mass), 
psychomotor development and appetite, to reduce the risk of hypoglycaemia, and to 
optimise linear growth. (A++) 
8.4 Treat with GH as soon as possible; starting at age 2–4 years is adequate for the 
majority of patients; however, due consideration should be given to the exceptions 
listed below*. (A++)  
8.5 Start GH at a dose of approximately 35 μg/kg per day. Use the lowest dose that results 
in catch-up growth. (A+++) 
8.6 Terminate GH therapy when height velocity is <2 cm per year over a 6-month period 
and bone age >14 years (female patients) or >17 years (male patients). (A++) 
8.7 If response to GH is poor, re-evaluate the underlying diagnosis, GH dose, IGF-1 
response, adherence to therapy and other confounding systemic problems. (A+++) 
8.8 Monitor circulating levels of IGF-1 and IGFBP-3 at least yearly during GH treatment. 
(A++)  
 
*GH treatment does not have a specific indication for SRS and is prescribed under the SGA indication 
(height SDS -2.5; age >2–4 years; dose 35–70 µg/kg per day) 106. Exemptions from the current 
SGA licensed indication used in some centres include starting GH therapy below the age of 2 
years in case of: severe fasting hypoglycaemia; severe malnutrition, despite nutritional support, 
which will lead to gastrostomy if no improvement is seen; and severe muscular hypotonia 
 
[H2] Bone age advancement and puberty 
The published literature on the natural history of bone age progression in patients with SRS 
is limited. Early bone age delay is followed by rapid advancement typically around 8–9 years 
3,81,113 but sometimes much younger especially in non-volitionally overfed children. Onset of 
puberty is usually within the normal range (8 to 13 years in girls and 9 to 14 years in boys) 114 
but at the younger end of the spectrum 3,73,87,115. Adrenarche can be early and aggressive in 
comparison with children born with non-SRS SGA, particularly in those with 11p15 LOM 116.  
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Our experience is that in patients with SRS and early adrenarche, the onset of central 
puberty might be earlier and the tempo faster than expected. In the last decades, population 
studies analysing the timing of normal puberty observed a mean age of puberty onset of 9.7 
to 10 years in girls 114. As a group, girls with SRS seem to start central puberty at a mean age 
of 9.1 years (I. Netchine, unpublished work). This early puberty further accelerates bone age 
maturation, which leads to an attenuated pubertal growth spurt and compromised adult 
height. Children with upd(7)mat are more likely to progress to central puberty even younger 
(mean starting age 8.5 years in girls and 9.5 years in boys) (I. Netchine, unpublished work). A 
rapid increase in BMI might also exacerbate the tendency to early adrenarche and central 
puberty 117-119. 
The window for effective GH treatment seems to be shorter in SRS patients than non-SRS 
SGA patients. In a recent study comparing a cohort of patients with SRS and a cohort of 
patients born SGA non-SRS, puberty started significantly earlier in the former (at 10.2 years 
versus 11.2 years in girls with SRS and non-SRS SGA, respectively, and at 11.4 years 
versus 12.0 years in boys with SRS and non-SRS SGA, respectively) 87. Furthermore, a 
steeper decline in height SDS from the onset of puberty until adult height was seen, which 
contributed to a lower adult height and a larger distance to target height than in non-SRS 
SGA patients. However, in 17 patients with SRS in this study, puberty was postponed for two 
years with gonadotropin-releasing hormone analogue (GnRHa) due to a low predicted adult 
height. The effect of GnRHa on final height has been analysed previously by the same 
authors in a cohort of SGA patients, including SRS patients120,121. This analysis suggested 
that the combination of GnRHa, started at the initiation of puberty and continued for at least 2 
years, along with GH treatment, improves adult height in patients born SGA with a poor adult 
height prognosis. A retrospective study of GnRHa treatment specifically in patients with SRS 
did not detect an effect of GnRHa on adult height, but this therapy was used in only 16 of 37 
patients and was not standardised 104. Further studies are required to specifically look at its 
effects in patients with SRS.  
Aromatase catalyses the rate-limiting step in the conversion of androstenedione to oestrone 
and testosterone to oestradiol. In patients with adrenarche with advancing bone age, but 
without central puberty, third-generation aromatase inhibitors (such as anastrozole) might be 
helpful in preventing rapid bone maturation, but are currently not indicated for growth 
disorders 122. An 18-month double-blind clinical trial is currently underway to study the 
efficacy and tolerance of treatment with anastrozole to slow bone maturation related to 
pathological adrenarche in patients with SRS and Prader–Willi syndrome 123. 
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Recommendations 
9.1 Monitor for signs of premature adrenarche, relatively early and accelerated central 
puberty, and insulin resistance. (A+++) 
9.2 Monitor and anticipate acceleration of bone age especially from mid childhood. (A++) 
9.3 Consider personalised treatment with GnRHa for at least 2 years in children with 
evidence of central puberty (starting no later than 12 years in girls and 13 years in 
boys) to preserve adult height potential. (A++) 
 
[H2] Long-term metabolic complications 
Individuals born with a low birth weight are at increased risk of adult health problems 
including coronary heart disease 124-126, hypertension, dyslipidaemia, insulin resistance and 
obesity (the metabolic syndrome) 127-130. Studies of children born SGA indicate that those who 
have rapid or disproportionate catch-up in weight are at particularly high risk 119,131,132.  
Insulin resistance in young, pre-pubertal, children with SRS can be atypical and difficult to 
detect in the fasting state; however, impaired glucose tolerance can be confirmed on formal 
oral glucose tolerance testing 133,134. Insulin resistance becomes more classic in the pubertal 
or post-pubertal age groups with elevation in fasting levels of glucose and insulin, and 
possibly the development of type 2 diabetes mellitus 135,136.  
Overall, GH therapy seems to have positive metabolic effects in children born SGA137, 
although specific data on such effects in SRS are lacking. Many studies of long-term GH 
treatment in children born SGA have shown positive outcomes, including increased lean 
body mass, reduced fat mass, decreased blood pressure and improvement in lipid profile 
107,120,137,138, which might last after discontinuation of therapy 138,139.  
In a study of 110 children born SGA treated with GH, those with the highest baseline levels of 
IGF-1 were the least insulin sensitive. Gains in height and IGF-1 response were positively 
associated with insulin secretion 140. In SRS, children with 11p15 LOM seem to be at a higher 
metabolic risk due to poor muscle mass and raised levels of IGF-1 than children who have 
upd(7)mat and other children born SGA 15,16,73,87. Further research is, therefore, required on 
the long-term effects of GH therapy on body composition and metabolic parameters in SRS 
and its various genotypes. 
  
Recommendations 
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10.1 Avoid excessive or rapid weight gain to prevent increased insulin resistance, which is 
associated with early and rapidly advancing adrenarche, early central puberty, and, in 
girls, a future risk of developing polycystic ovary syndrome. (A++) 
10.2 Raise awareness among gastroenterologists, dieticians, neonatologists, paediatricians 
and primary health-care providers of the importance of not overfeeding this group of 
children. (A+++) 
10.3 Advise parents, grandparents and care-givers about the risk of insulin resistance 
associated with intrauterine growth retardation and overfeeding. (A+++) 
10.4 Screen for physical and biochemical indicators of insulin resistance during GH 
treatment, especially in children with low muscle mass and high baseline levels of IGF-
1. (A+) 
10.5 In patients with clinical signs of insulin resistance, consider formal assessment of 
insulin sensitivity with a 2-h oral glucose tolerance test including insulin and C-peptide 
levels (A++) 
10.6 Advocate a healthy diet and lifestyle in older children and young adults with particular 
emphasis on protein calorie balance and regular exercise to avoid disproportionate 
weight gain, particularly after discontinuation of GH treatment. (A+++) 
 
[H2] Neurocognitive problems  
Motor and speech delay are common in children with SRS 4,16-18,20  (Table 2). Motor delay 
might be related to reduced muscle bulk and fairly large head size. Verbal dyspraxia and 
more global developmental delay or learning difficulties, usually mild, have been described in 
some children with SRS, particularly those with upd(7)mat 12,15,16,20,141. Autistic spectrum 
disorder has also been reported more frequently in this subgroup than in the other subgroups 
of SRS 15. Myoclonus-dystonia in patients with upd(7)mat is probably associated with altered 
expression of the paternally-expressed SGCE on chromosome 7q21 20,40,142,143.  
 
Recommendations  
11.1 Refer infants and children with SRS for a developmental assessment when necessary 
to ensure appropriate intervention as early as possible. (A+++) 
11.2 In patients with upd(7)mat, check for symptoms of myoclonus-dystonia at each clinical 
appointment and refer early to a paediatric neurologist if required. (A+++) 
11.3 Monitor children with upd(7)mat for signs of verbal or oromotor dyspraxia and/or signs 
of autistic spectrum disorders. (A+++) 
11.4 Inform parents about increased risk of speech, oromotor and learning disabilities 
(especially in those with upd(7)mat). (A+++) 
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11.5 Follow school-age children for any learning difficulties, psychosocial challenges and/or 
cognitive delay, to enable appropriate intervention. (A+++) 
 
[H2] Orthopaedic problems 
Orthopaedic problems seen in association with SRS include limb or body asymmetry, 
scoliosis, hip dysplasia and hand and/or foot anomalies (table 2).  
Limb asymmetry can affect the arms, legs or both. In seven patients with clinically-diagnosed 
SRS, limb length discrepancy was not significantly affected by GH treatment 144. Limb 
lengthening surgery performed to equalize limb lengths in patients with SRS has shown 
positive results 145.  
Scoliosis has been reported in 9–36% of individuals with SRS 20,146,147. The causal 
relationship to leg length asymmetry is not clear 146,147. Associated back pain has been 
reported inconsistently 5,146. GH therapy might be associated with worsening of existing 
scoliosis; however, causality has not been established 148. A study in a large group of children 
with Prader–Willi syndrome (another imprinting disorder, whose clinical features include like 
SRS growth failure, infant hypotonia, early feeding difficulties and an increased risk of 
scoliosis) has clearly shown that GH therapy does not influence onset and progression of 
scoliosis 149 but specific studies are required to determine whether GH therapy modifies 
scoliosis risk in SRS. 
 
Recommendations 
12.1 Where necessary, refer to a paediatric orthopaedic surgeon for collaborative 
management of body asymmetry, limb length discrepancy and scoliosis. (A+++) 
12.2 Routinely examine all patients with SRS for scoliosis. (A+++) 
12.3 Before initiation of GH therapy, refer patients with scoliosis to the orthopaedic team and 
monitor while receiving GH. (A+++) 
12.4 Evaluate leg length asymmetry regularly and consider orthopaedic management if 
necessary. (A++) 
 
[H2] Maxillofacial abnormalities 
SRS is characterized by craniofacial disproportion, which results in a triangular-shaped face 
95.  Delayed dental eruption, microdontia, absence of secondary teeth and blunted condyles 
have all been reported in patients with SRS 150,151.  
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In our experience, the upper jaw arch is frequently narrow and crowded, but in the lower arch 
crowding might be severe, with displacement of lower incisors into a lingual position. 
Micrognathia is frequent, with lack of mandibular growth, which results in a small, pointed 
chin and an overbite. Children with notable facial asymmetry might have a crossbite that 
impairs normal chewing. Velopharyngeal insufficiency with or without a submucous cleft is 
quite common in patients with 11p15 LOM SRS 20. Otitis media is frequent in young children 
with SRS 7 and seems to be improved by orthodontic treatment 152.  
 
Orthodontic intervention in children with SRS can help normalize oropharangeal function and 
facial appearance. An experienced craniofacial team, including orthodontists, plastic 
surgeons and ear, nose and throat surgeons is ideal. Multiple orthodontic techniques have 
been used successfully 153. Currently, rapid palatal expansion is the most effective technique 
to change the shape of the face 154. 
 
Many patients with SRS report excessive daytime fatigue, snoring and/or disrupted sleep. 
However, data are very limited regarding sleep problems, including sleep disordered 
breathing, in association with SRS. A retrospective study identified mild sleep disordered 
breathing in 74% of patients with SRS, (not exacerbated with GH therapy) 155. Further studies 
are necessary.  
 
Recommendations 
13.1 Develop a referral relationship with a maxillofacial team or orthodontist who has 
experience caring for patients with SRS. (A++) 
13.2 Refer patients to the maxillofacial team for assessment after eruption of primary 
dentition when necessary. (A++) 
13.3 Encourage early orthodontic intervention and compliance with follow-up. (A+) 
13.4 Screen for symptoms of sleep disordered breathing (such as snoring, apnoeas, 
excessive daytime fatigue, disrupted sleep and agitation). (A++) 
13.5 Refer patients with suspected sleep disordered breathing to the appropriate specialist 
for evaluation of obstructive sleep apnoea. (A++) 
 
[H2] Other congenital anomalies 
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Congenital anomalies have been described in a minority of patients with SRS, particularly 
those with 11p15 LOM (supplementary table 1 online). Genital abnormalities, including 
cryptorchidism and hypospadias, occur frequently in boys 16,20. Mayer–Rokitansky–Kuster–
Hauser syndrome in female patients is characterised by congenital hypoplasia or aplasia of 
the uterus and upper part of the vagina 16,18,156,157. Structural renal anomalies 18,20 and 
congenital heart defects 4,18,20,158 have also been reported.  
 
Recommendations 
14.1 Investigate genital abnormalities in boys. (A+++) 
14.2 Investigate girls with primary amenorrhoea for Mayer–Rokitansky–Kuster–Hauser 
syndrome. (A+++) 
 
[H2] Adulthood 
Very little information exists in the literature regarding the long-term natural history of SRS. 
The majority of individuals with SRS are not routinely followed up, and the small numbers of 
adults reported have few medical problems. However, it is well recognised that being SGA at 
birth with accelerated gain in weight for length, particularly during early life, increases the risk 
of metabolic problems in adulthood 119,132,159 (see previous discussion). Medical problems 
reported in adults with 11p15 LOM include hypertension, dilated cardiomyopathy, type 2 
diabetes mellitus, hypercholesterolaemia, fatty liver infiltration, elevated glucose levels and 
raised HbA1c 135,136,160 but these reports might not be representative of the population as a 
whole.  
 
Recommendations 
15.1 Consider medical follow-up of adolescents and young adult patients with SRS or 
develop collaboration with a general or internal medicine team for follow-up. (A+++) 
15.2 Avoid losing contact with adult patients with SRS, to facilitate their participation in and 
potential benefit from future clinical research. (A+++) 
 
[H1] Genetic counselling 
Accurate genetic counselling depends on the underlying molecular cause. 11p15 LOM is 
associated with a low recurrence and offspring risk, although empirical figures are not 
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available. Only three sibships with 11p15 LOM are reported in the literature 13,20, and the 
underlying mechanism is unknown in all three.  
The potential for a familial trans-acting gene mutation suggests that the recurrence risk in 
patients with SRS and MLID; may potentially be higher than other SRS cases; however, 
evidence to support this supposition does not yet exist. 
 
Rare familial cases of SRS have been reported with underlying mechanisms including: 
maternally inherited 11p15 duplication 24,26 (supplementary table 2 online); maternally 
inherited CDKN1C gain-of-function mutations 60; and paternally inherited IGF2 loss-of-
function mutations 61. In these families, the risk of recurrence might be as high as 50%. 
Investigation for underlying CNVs in patients with 11p15 LOM is, therefore, important. 
upd(7)mat is associated with a low recurrence and offspring risk (if the karyotype of the 
patient is normal)50. Data are limited regarding the risk of parents of children with clinically 
diagnosed SRS having another child with SRS; however, the overall risk is probably low. 
Similarly, the offspring risk for individuals with clinically diagnosed SRS is likely to be low. 
 
Recommendation 
16.1 Genetic counselling should be performed by a health professional experienced in the 
field of imprinting disorders. As the recurrence risk associated with CNVs is dependent 
on their size, location and parental origin, these should be taken into consideration 
during counselling for the family. (A+++) 
[H1] Conclusions 
Children with SRS and their families face challenges from birth to adulthood. In addition to 
the problems associated with being born SGA, clinicians treating patients with SRS need to 
be aware of syndrome-specific management issues. These include substantial feeding 
difficulties, severe postnatal growth failure with no catch-up, recurrent hypoglycaemia, 
premature adrenarche, fairly early and rapid puberty, insulin resistance, body asymmetry, 
orthodontic issues, sleep disordered breathing and the potential for other congenital 
anomalies.  
Presented here are the first international consensus guidelines for the diagnosis and 
management of SRS, based on published evidence and expert opinion. A summary of all 72 
recommendations, including a flow chart for the investigation and diagnosis of SRS, is 
available as supplementary information online.  
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These management recommendations apply to all patients clinically diagnosed with SRS, 
both with and without a molecularly confirmed diagnosis. However, identification of the 
underlying molecular subtype can guide treatment with regard to specific risk factors. 
Management should involve a multi-disciplinary approach and close parental guidance. A 
practical checklist for use in routine clinical follow up of these patients is proposed in Table 5. 
As there are limited published data specific to SRS, many questions remain (Box 2). 
International collaboration and further research is urgently needed to better inform the 
investigation and management of patients with SRS in the future. 
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Box 1: Definitions 
Small for gestational age (SGA) 
Weight and/or length less than -2 SDS for gestational age at birth, based on accurate 
anthropometry at birth (including weight, length and head circumference) and reference data 
from a relevant population 106. 
Intrauterine growth retardation (IUGR) 
Also known as intrauterine growth restriction, this diagnosis is based on at least two 
ultrasonography measurements at least 2 weeks apart, with fetal weight below 10th percentile 
for gestational age. IUGR might or might not result in a baby born SGA161. 
Silver–Russell syndrome (SRS) 
A distinct syndromic growth disorder in which prenatal and postnatal growth failure are 
associated with other characteristic features, including relative macrocephaly at birth, 
protruding forehead in early life, body asymmetry and substantial feeding difficulties. Almost 
all children with SRS are born SGA. Postnatal catch-up growth is not seen in the vast 
majority of children with SRS. 
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Box 2: Future research directions for SRS 
 
Abbreviations: ART, assisted reproductive technology; GH, growth hormone; GnRH, gonadotropin-
releasing hormone; IGF1, insulin-like growth factor 1; MLID, multi-locus imprinting disturbance 
  
Clinical  
• Incidence and/or prevalence  
• Frequency of associated features (for example, scoliosis, sleep disordered 
breathing, developmental delay, behavioural issues) 
• Frequency and associated phenotype of molecular subtypes  
o 11p15, upd(7)mat 
o MLID 
o 14q32 abnormalities, UPD(20)mat, UPD(16)mat 
• Clinical overlap with other imprinting disorders 
Molecular  
• Development of testing methodology 
• Identification of additional molecular causes in patients with clinically diagnosed 
SRS  
• Prenatal testing: methodology, ethical implications   
Management 
• Use of cyproheptadine as appetite stimulant 
• Optimal timing of GH use 
• Interpretation of IGF-1 levels 
• Role of aromatase inhibitors to control bone age advancement 
• GnRH analogue inhibition of central puberty 
• Control of postnatal weight gain 
• Limb lengthening 
SRS in adulthood 
• Natural history, including risk of metabolic syndrome 
• Quality of life indicators 
• Reproductive issues (ART, recurrence risk associated with MLID) 
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Table 1: Netchine-Harbison clinical scoring system 
 
Clinical criteria 
 
Definition 
SGA (birth weight and/or birth length) ≤ -2 SDS for gestational age 
Postnatal growth failure 
 
Height at 24±1 months ≤ -2SDS or height ≤ -
2SDS below mid-parental target height 
Relative macrocephaly at birth 
 
Head circumference at birth ≥1.5 SDS above birth 
weight and/or length SDS 
Protruding forehead* 
 
Forehead projecting beyond the facial plane on a 
side view as a toddler (1–3 years) 
Body asymmetry 
 
LLD of ≥0.5 cm or arm asymmetry or LLD <0.5 
cm with at least two other asymmetrical body 
parts (one non-face) 
Feeding difficulties and/or low BMI 
 
BMI ≤ -2SDS at 24 months or current use of a 
feeding tube or cyproheptadine for appetite 
stimulation  
Clinical diagnosis is considered if patient scores at least four out of six from these criteria. If 
all molecular test are normal and differential diagnoses have been ruled out, patients scoring 
at least four of six criteria, including both prominent forehead and relative macrocephaly 
should be diagnosed as clinical SRS. *Protruding forehead is equivalent to ‘prominent forehead’ 
162. Abbreviations: LLD, leg length discrepancy; SDS, SD score; SGA, small for gestational age. 
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Table 2: Additional clinical features of SRS 
Clinical feature 
Frequency  
% (total no. patients) 
Reference 
Triangular face 94 (164) 16-18 
5th finger clinodactyly 75 (319) 4,15-18,20  
Shoulder dimples 66 (61) 15 
Micrognathia 62 (115) 16,18,20 
Low muscle mass 56 (103) 15,16 
Excessive sweating 54 (106) 16,20 
Low-set and/or posteriorly rotated ears 49 (266) 15-17,20 
Down-turned mouth 48 (176) 15,16,18,20 
High pitched or squeaky voice 45 (26) 16 
Prominent heels 44 (61) 15 
Delayed closure of fontanelle 43 (47) 18,20 
Male genital abnormalities  40 (85) 15,16,18,20 
Speech delay 40 (189) 16,17,20 
Irregular or crowded teeth 37 (195) 16-18,20 
Motor delay 37 (254) 4,16-18,20 
Syndactyly of toes 30 (264) 15-17,20 
Hypoglycaemia 22 (103) 4,20 
Scoliosis and/or kyphosis 18 (227) 16,20,147 
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Table 3- Differential diagnosis of SRS in patients with relative microcephaly  
Feature Syndrome (OMIM number) 
Bloom syndrome 
(#210900) 
 
Nijmegen 
breakage 
syndrome 
(#251260) 
 
MOPD II
(#210720) 
Meier–Gorlin 
syndrome 
(#224690, 
#61380, 
#613803, 
#613804, 
#613805) 
IGF1R 
mutation or 
deletion 
(#147370, 
#612626) 
IGF1
mutation 
(#147440) 
Birth weight 
SDS 
Mean -4.6 
 
Mean -1.6 
 
Mean -3.9  
 
 
 
Mean -3.8  
 
-1.5 to -4.9 -2.5 to -4.5  
Adult 
height 
range (cm) 
Male patients: 
128-164 
 
Female patients:  
115-160 
Male patients: 
161-172 
 
Female patients: 
150-165 
Mean 96  
 
 
  
Male patients:  
136-157  
 
Female patients: 
127-150  
 
IGF1R 
mutation: 
1 female 
patient - 140  
2 male 
patients - 133 
and 170 
1 male patient: 
117 
Cognitive 
function 
Usually normal At pre-school age 
IQ normal or 
borderline;  
progressive 
deterioration to 
moderate mental 
retardation 
Variable:  
none / mild ID 
(majority), 
occasionally 
severe ID 
90% normal IQ, 
occasionally 
mild or 
moderate ID 
 
Variable: 
normal 
(~50%), mild 
ID (25%), 
moderate or 
severe ID 
(25%) 
Severe ID 
Facial 
features 
Narrow face with 
underdeveloped 
malar area and 
mandible, fairly 
prominent nose, 
sun sensitive 
telangiectasia in 
malar distribution 
Receding 
forehead, 
prominent mid-
face, small 
mandible, up-
slanting palpebral 
fissures, long 
nose and philtrum, 
large ears  
Prominent, long, 
broad nose with 
hypoplastic tip, 
low insertion of 
columella, 
prominent eyes in 
infancy, 
micrognathia 
Microtia, narrow, 
beaked nose 
with low 
insertion of 
columella, small 
mouth, 
retrognathia 
IGF1R 
mutation: often 
normal; 
triangular face, 
micrognathia.  
 
15q26-qter 
deletion: 
micrognathia 
No consistent 
features 
reported 
Other 
features 
Patchy areas of 
hypopigmented 
and 
hyperpigmented 
skin, feeding 
difficulties, high 
tumour risk (44% 
develop cancer by 
age 25), 
hypogonadism, 
type 2 diabetes 
mellitus, 
immunodeficiency, 
chromosomal 
instability with 
increased 
frequency of sister 
chromatid 
exchange 
Severe, 
progressive 
microcephaly, 
immunodeficiency, 
cancer 
predisposition, 
chromosomal 
instability and 
rearrangements, 
café au lait spots, 
premature ovarian 
failure 
  
Mean OFC at 
birth -4.6 SDS, 
progressive 
microcephaly, 
mesomelic limb 
shortening, 
progressive 
metaphyseal 
bone dysplasia, 
hip dysplasia, 
acanthosis 
nigricans, insulin 
resistance, 
cryptorchidism, 
intracranial 
aneurysm, dental 
anomalies, 
squeaky voice 
 
Patellar 
hypoplasia, 
pulmonary 
emphysema, 
cryptorchidism, 
mammary 
hypoplasia 
(post-pubertal 
100%), 
hypoplastic 
labiae  
 
IGF1R 
mutation: 
pectus 
excavatum, 5th 
finger 
clinodactyly, 
short fingers 
 
15q26-qter 
deletion: fifth 
finger 
clinodactyly, 
short fingers, 
talipes, 
congenital 
heart disease, 
renal 
anomalies 
Sensorineural 
deafness 
Inheritance 
or 
molecular 
abnormality 
Autosomal 
recessive  
 
Mutations in 
RECQL3 
 
High prevalence in 
Ashkenazi Jewish 
population 
Autosomal 
recessive 
 
Mutations in NBN  
 
 
High prevalence in 
Slavic population  
Autosomal 
recessive  
 
Mutations in 
PCNT 
Autosomal 
recessive 
 
Mutations in 
ORC1, ORC4, 
ORC6, CDT1, 
CDC6 
IGF1R 
mutation: 
majority 
autosomal 
dominant; 
compound 
heterozygosity 
reported in 2 
cases 
Autosomal 
recessive  
 
Mutations in 
IGF1 
Abbreviations: ID, intellectual disability; MOPD II, microcephalic osteodysplastic primordial dwarfism type II; OFC, 
occipito-frontal circumference. 
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Table 4: Differential diagnosis of SRS in patients with relative normocephaly or 
macrocephaly 
Feature Syndrome (#OMIM number) 
3-M syndrome 
(#273750) 
 
Mulibrey nanism 
(#253250) 
SHORT syndrome 
(#269880) 
Floating harbour 
syndrome 
(#136140)
IMAGe syndrome 
(#614732) 
Birth weight 
SDS 
Mean: -3.1 
 
Mean: -2·8  
(range -4.0 to 0.5) 
 
Mean: -3.3 Mean: -2.5 -2.0 to -4.0 
Adult height 
range (cm) 
115-150 136-150 Mean 154 Female patients: 
98-156  
 
Male patients:  
106-164 
 
1 male patient: 160 
 
1 female patient: 
143 
Cognitive 
function 
Normal  
 
Mild motor and 
speech delay only 
Normal Delayed speech. 
Intellect variable: 
normal to significant 
ID 
 
Normal or mild ID 
Facial 
features 
Anteverted nares, 
full lips, mid-face 
hypoplasia, long 
philtrum  
 
Triangular face, 
frontal bossing 
Micrognathia, high 
broad forehead, 
triangular-shaped 
face, deep-set eyes, 
prominent nose, 
low-set posteriorly 
rotated ears, 
hypoplastic nasal 
alae, facial 
lipodystrophy, thin 
hair 
Triangular face, 
deep-set eyes, long 
eyelashes, bulbous 
nose, wide 
columella, short 
philtrum, thin lips 
Frontal bossing, 
low-set ears, flat 
nasal bridge, short 
nose 
Other 
features 
Prominent heels 
(also in upd(7)mat), 
short broad neck, 
pectus deformity, 
short thorax, 
winged scapulae, 
hyperlordosis, hip 
dysplasia, subtle 
radiographic 
changes (slender 
long bones, tall 
vertebral bodies) 
 
Hepatomegaly, 
yellow spots on 
retina, progressive 
restrictive 
perimyocarditis, 
insulin resistance, 
high pitched voice, 
slender long bones 
with thick cortex 
and narrow 
medullar channels, 
shallow sella 
turcica, increased 
tumour risk 
(particularly Wilms 
and ovarian stromal 
tumours) 
Rieger anomaly, 
dental delay, partial 
lipodystrophy, 
transparent skin, 
dimples on elbows 
and buttocks, 
herniae, fifth finger 
clinodactyly, 
hyperextensible 
joints, 
hypogonadism, high 
pitched voice, type 
2 diabetes mellitus, 
nephrocalcinosis, 
thin gracile bones, 
Delayed speech 
development with 
expressive 
language delay, 
significantly delayed 
bone age, broad 
fingertips 
Congenital adrenal 
hypoplasia, 
metaphyseal and/or 
epiphyseal 
dysplasia, male 
genital anomalies 
Inheritance 
or 
molecular 
abnormality 
Autosomal 
recessive 
 
Mutations in CUL7, 
OBSL1, CCDC8 
 
Autosomal 
recessive  
 
Mutations in 
TRIM37 
 
High prevalence in 
Finnish population  
Autosomal 
dominant  
 
Mutations in 
PIK3R1  
 
Autosomal 
dominant 
 
Mutations in 
SRCAP 
Imprinted –  
Maternally inherited 
mutations in 
CDKN1C 
 
Abbreviation: ID, intellectual disability 
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Table 5: Clinical checklist for management of patients with SRS 
 
At 
diagnosis 
0-2 years 2-10 
years 
10-18 
years 
Document molecular subtype 
Provide support group information 
Genetic counselling for parents 
Feeding and growth 
Exclude feeding difficulties    □ □ 
Ensure nutritional repletion     
Screen for gut dysmotility    □ □ 
Screen for oromotor or sensory issues  □ □ □ 
Avoid rapid postnatal/childhood weight 
gain     
Measure head circumference     
Measure and monitor linear growth     
Calculate and monitor BMI      
Screen for symptoms/signs of 
hypoglycaemia   □ □ 
Consider growth hormone treatment  □   
Monitor IGF-1 or IGFBP3 levels (more 
than yearly)  □  
Monitor clinically (with or without
biochemical testing) for insulin 
resistance 
 N/A  
Adrenarche and puberty  
Monitor clinically for early adrenarche    N/A 
Anticipate early bone age 
advancement  N/A   
Consider treatment of early or rapid 
central puberty  N/A  □ 
Other medical 
Monitor for symptoms of sleep 
disordered breathing     
Orthodontic or dental  □   
Ear, nose and throat  □ □ □ 
Neurodevelopment 
Developmental assessment   □ □ 
Screen for myoclonus-dystonia*     
Speech and language evaluation    □ 
School progress  N/A □ □
Monitor for speech, motor and 
cognitive difficulties  □  □ 
Psychosocial evaluation  N/A □ □ 
Musculoskeletal 
Limb length discrepancy or asymmetry  □ □ □ 
Scoliosis  □ □ □ 
Screen for hip dysplasia   □ □ 
 
N/A not applicable;  
Assessment recommended (unless N/A to age group) 
□ Assessment may be considered, depending on the clinical features of the patient [Au: We 
cannot use blocks in this way. OK to replace with AR and AC, respectively?] [Ed: can 
we use R and C, to be defined as ‘recommend assessment’ and ‘consider assessment’ ?.  
The letter A at the beginning of every acronym will reduce clarity.  
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*upd(7)mat only 
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Figure legends: 
Figure1: Flow chart for investigation and diagnosis of SRS. Diagnostic questions in blue 
boxes; recommended molecular testing in yellow boxes. Green boxes: diagnosis of SRS 
confirmed; pink boxes: diagnosis not confirmed. Abbreviations: CNV, copy number variant. 
NH-CSS, Netchine-Harbison clinical scoring system; SRS, Silver–Russell syndrome. 
 
Figure 2A: Representation of the 11p15 region, showing both centromeric and telomeric 
domains. Only the imprinted genes that are implicated in the pathophysiology of Silver–
Russell syndrome are represented. Blue boxes: paternally expressed genes (the growth 
promoter IGF2 and the long non coding RNA (lncRNA) KCNQ1OT1). Pink boxes: maternally 
expressed genes (the growth inhibitor CDKN1C, the ion channel KCNQ1 and the non-coding 
RNA H19). Circles: Differentially methylated regions (DMRs). Black circles: methylated 
DMRs. White circles: unmethylated imprinting control regions (ICRs). 
 
Figure 2B: Structure of the IGF2/H19 DMR. This DMR contains short repetitive blocks of 
sequence and harbours seven binding sites for the zinc finger protein CTCF (green). Multiple 
enhancer elements (grey ovals) distal to H19 are shared between H19 and IGF2, able to 
increase expression of either. Binding of CTCF to the unmethylated maternal DMR blocks 
interactions between the IGF2 promoter and enhancers downstream of H19, which results in 
maternal H19 expression. Conversely, methylation of ICR1 on the paternal allele prevents 
CTCF binding, enabling interaction between the IGF2 promoter and distal enhancers, and 
thus paternal IGF2 expression 163,164.  
 
Figure 3: Mutations and epimutations of the imprinted region at chromosome 11p15 
associated with Silver–Russell syndrome. The structure of the 11p15 region is represented 
as in figure 2. Paternal hypomethylation of H19/IGF2 IG-DMR results in loss of paternal IGF2 
and gain of maternal H19 expression, which leads to a growth restriction phenotype 9. Less 
commonly, maternal duplication of the centromeric or both domains results in growth 
retardation due to increased dosage of CDKN1C; however, smaller CNVs should be 
classified with caution due to the complex regulation of the region 27. Rare familial cases 
have been associated with a maternal CDKN1C gain-of-function mutation (green cross) 60 or 
a paternal IGF2 loss-of-function mutation (red cross)61.  
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